VONVENDI Dosing for 3 Indications1

style
Flush, primary secondary horizontal, Content Width LG, Dark
style
Flush

Indications

VONVENDI [von Willebrand factor (recombinant)] is indicated in adult and pediatric patients with von Willebrand disease (VWD) for1:

For adult patients only:

style
Content Width SM, tight

Your adult patient's prophylaxis journey begins with a straightforward dosing approach1

Your patients’ journey begins with a single starting dose with a single factor1

For routine prophylaxis, administer: 40 to 60 IU/kg of VONVENDI twice weekly for initiation of prophylactic treatment1

style
Content Width SM, Center
id
Prophylaxis-dosing
style
Content Width SM, flush
Consider self-infusion with VONVENDI for your patients with VWD

Get patient resources

style
Center, Light Blue, Contained SM

VONVENDI for on-demand treatment may be dosed with or without rFVIII1*

VONVENDI enables healthcare providers to manage von Willebrand factor (VWF) and FVIII levels separately and specifically, based on patient need1†‡

For the first dose, administer VONVENDI alone if FVIII:C level is ≥40% or if an immediate rise in FVIII:C is not necessary.1

style
Center, Content Width SM
id
On-demand-dosing
{colspan: 3} DOSING GUIDELINES FOR TREATMENT OF MINOR AND MAJOR HEMORRHAGES1
Row Background (Light Blue)
Hemorrhagic event
Initial dose†
Subsequent dose
Minor (eg, readily managed epistaxis, oral bleeding, menorrhagia)
40 to 50 IU/kg
40 to 50 IU/kg every 8 to 24 hours (as clinically required)
Major‡ (eg, severe or refractory epistaxis, menorrhagia, gastrointestinal [GI] bleeding, central nervous system [CNS] trauma, hemarthrosis, or traumatic hemorrhage)
50 to 80 IU/kg
40 to 60 IU/kg every 8 to 24 hours for approximately 2 to 3 days (as clinically required)

*VONVENDI contains only trace amounts of rFVIII.1
†If rFVIII is administered, see rFVIII package insert for reconstitution and administration instructions.1
‡A bleed could be considered major if red blood cell transfusion is either required or potentially indicated or if bleeding occurs in a critical anatomical site (eg, intracranial or gastrointestinal hemorrhage).1

style
Content Width SM

Administer VONVENDI with rFVIII if the FVIII:C level is less than 40%, or is unknown, to control bleeding. The rFVIII dose should be calculated according to the difference between the patient’s baseline plasma FVIII:C level, and the desired peak FVIII:C level to achieve an appropriate plasma FVIII:C level based on the approximate mean recovery of 2 (IU/dL)/(IU/kg). Administer the complete dose of VONVENDI followed by rFVIII within 10 minutes.1

Learn about the endogenous rise in FVIII levels following VONVENDI infusion.

style
Center, Content Width SM
Consider prophylaxis for your adult VWD patients

View prophylaxis data

style
Center, Light Blue, Contained SM

VONVENDI for management of surgical bleeding may be dosed with or without rFVIII1*

Perioperative dosing of VONVENDI for elective surgery†

style
Center, Primary Text, Content Width SM
id
Surgical-dosing

12-24 hours prior to surgery1:

VONVENDI may be administered to allow endogenous FVIII levels to increase

Within 3 hours prior to surgery1:

  • Assess FVIII:C to ensure minimum target levels are achieved
  • Administer VONVENDI within 1 hour prior to surgery with or without rFVIII
    • Administer VONVENDI alone if FVIII:C is at or greater than minimum target levels
    • Administer VONVENDI with rFVIII if FVIII:C is below minimum target levels
style
Content Width XS
https://vwd-day-0--vonvendihcp-day0--onetakeda.aem.page/fragments/dosing-columns
style
Content Width SM
{colspan: 7} CALCULATION OF VONVENDI DOSING1
Row Background (Light Blue Accent)
{colspan: 4} Baseline FVIII:C, VWF:RCo, IR‡
{colspan: 2} Target Peak Plasma Levels
Row Background (Blue Accent)
{colspan: 2} Known
{colspan: 2} Unknown
Type of Surgery
{colspan: 2} Calculation of VONVENDI Dose (IU VWF:RCo required)
VWF:RCo [IU VWF:RCo/ kgBW]
FVIII:C (IU FVIII:C/ kgBW]
VWF:RCo
FVIII:C§
Row Background (Brand Neutral)
Minor
{rowspan: 2, colspan: 2} Equation from Vonvendi dosing chart showing VWF:RCo dosage adjustment based on target peak, baseline, body weight in kilograms, and infusion rate, used for calculating dosing in surgical settings.
25 to 30 IU/kg
20 to 25 IU/kg
50% to 60%
40% to 50%
Row Background (Brand Neutral)
Major
50 ± 10 IU/kg
40 to 50 IU/kg
100%
80% to 100%
style
Content Width SM

After surgery1

  • Monitor VWF:RCo and FVIII:C plasma levels starting at 12-24 hours and at least every 24 hours
  • Dose VONVENDI with or without rFVIII based on patient need. If necessary, the frequency of VONVENDI dosing should range between twice a day and every 48 hours

Dosing of VONVENDI, with or without rFVIII, should be based on patient need as determined by monitoring levels and clinical judgment.1

style
Content Width XS

*VONVENDI contains only trace amounts of rFVIII.1
†Please see Full Prescribing Information for VONVENDI dosing in the emergency setting.1
‡IR=Incremental Recovery as measured in the subject. If the IR is not available, assume an IR of 2.0% per IU/kg.1
§Additional rFVIII may be required to attain the recommended FVIII:C target peak plasma levels. Dosing guidance should be based on the IR.1

style
Content Width SM
{colspan: 7} RECOMMENDED VWF:RCo AND FVIII:C MINIMUM TARGET PLASMA LEVELS1
{colspan: 2} VWF:RCo Minimum Target Plasma Level
{colspan: 2} FVIII:C Minimum Target Plasma Level
{rowspan: 2} Minimum Duration of Treatment
{rowspan: 2} Frequency of Dosing
Type of Surgery
Up to 72 hours post surgery
After 72 hours post surgery
Up to 72 hours post surgery
After 72 hours post surgery
Minor
≥30%
>30%
48 hours
{rowspan: 2} Every 12-24 hours to every other day
Major
>50%
>30%
>50%
>30%
72 hours
style
Content Width SM

Click to learn about VONVENDI for prophylaxis.

https://main--vonvendihcp--onetakeda.aem.page/dosing

Be a VONVENDI Prophylactivist

VONVENDI is the first and only recombinant VWF for prophylaxis1-5

Click to find support for your patients.

https://main--vonvendihcp--onetakeda.aem.page/resources/for-your-patients

Support for Your Patients

Browse a variety of resources from Takeda for your appropriate patients

Click to contact a Takeda Rep.

https://main--vonvendihcp--onetakeda.aem.page/find-a-rep

Contact a Takeda Rep

Get in touch with a Takeda representative in your area

background
style
Center, Spray paint background
References
  1. VONVENDI [von Willebrand factor (Recombinant)] Prescribing Information.
  2. HUMATE-P [Antihemophilic Factor/von Willebrand Factor Complex (Human)] Prescribing Information. CSL Behring GmbH; 2020.
  3. WILATE Full Prescribing Information. Paramus, NJ: Octapharma; rev December 2023.
  4. ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) Prescribing Information. Grifols.
  5. FDA Approves Prophylactic Treatment with VONVENDI [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD). Businesswire. Accessed August 14, 2025. https://www.businesswire.com/news/home/20220131005214/en/FDA-Approves-Prophylactic-Treatment-with-VONVENDI-von-Willebrand-Factor-Recombinant-for-Adult-Patients-Living-with-Severe-Type-3-von-Willebrand-Disease-VWD
style
References, Content Width SM